Raltegravir with optimized background therapy for resistant HIV-1 infection. (2008)
Steigbigel, Roy T, Cooper, David A, Kumar, Princy N, Eron, Joseph E, Schechter, Mauro, Markowitz, Martin, ...
BACKGROUND: Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs. METHODS: We...
A novel assay for the DNA strand-transfer reaction of HIV-1 integrase (1994)
Hazuda, Daria J., Hastings, Jeffrey C., Wolfe, Abigail L., Emini, Emilio A.
Espeseth, Amy S., Felock, Peter, Wolfe, Abigail, Witmer, Marc, Grobler, Jay, Anthony, Neville, ...
Diketo acids such as L-731,988 are potent inhibitors of HIV-1 integrase that inhibit integration and viral replication in cells. These compounds exhibit the unique ability to inhibit the strand...
Grobler, Jay A., Stillmock, Kara, Hu, Binghua, Witmer, Marc, Felock, Peter, Espeseth, Amy S., ...
The process of integrating the reverse-transcribed HIV-1 DNA into the host chromosomal DNA is catalyzed by the virally encoded enzyme integrase (IN). Integration requires two metal-dependent...
Lineberger, Janet E., Danzeisen, Renee, Hazuda, Daria J., Simon, Adam J., Miller, Michael D.
Human immunodeficiency virus (HIV) entry into a host cell requires the fusion of virus and cellular membranes that is driven by interaction of the viral envelope glycoproteins gp120 and gp41...
Hazuda, Daria J., Anthony, Neville J., Gomez, Robert P., Jolly, Samson M., Wai, John S., Zhuang, Linghang, ...
The increasing incidence of resistance to current HIV-1 therapy underscores the need to develop antiretroviral agents with new mechanisms of action. Integrase, one of three viral enzymes essential...
Olsen, David B., Eldrup, Anne B., Bartholomew, Linda, Bhat, Balkrishen, Bosserman, Michele R., Ceccacci, Alessandra, ...
Improved treatments for chronic hepatitis C virus (HCV) infection are needed due to the suboptimal response rates and deleterious side effects associated with current treatment options. The...
Ludmerer, Steven W., Graham, Donald J., Boots, Evelyn, Murray, Edward M., Simcoe, Amy, Markel, Eric J., ...
The innate genetic variability characteristic of chronic hepatitis C virus (HCV) infection makes drug resistance a concern in the clinical development of HCV inhibitors. To address this, a transient...
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope
Miller, Michael D., Geleziunas, Romas, Bianchi, Elisabetta, Lennard, Simon, Hrin, Renee, Zhang, Hangchun, ...
HIV-1 entry into cells is mediated by the envelope glycoprotein receptor-binding (gp120) and membrane fusion-promoting (gp41) subunits. The gp41 heptad repeat 1 (HR1) domain is the molecular target...
Espeseth, Amy S., Felock, Peter, Wolfe, Abigail, Witmer, Marc, Grobler, Jay, Anthony, Neville, ...
Diketo acids such as L-731,988 are potent inhibitors of HIV-1 integrase that inhibit integration and viral replication in cells. These compounds exhibit the unique ability to inhibit the strand...
Grobler, Jay A., Stillmock, Kara, Hu, Binghua, Witmer, Marc, Felock, Peter, Espeseth, Amy S., ...
The process of integrating the reverse-transcribed HIV-1 DNA into the host chromosomal DNA is catalyzed by the virally encoded enzyme integrase (IN). Integration requires two metal-dependent...
Lineberger, Janet E., Danzeisen, Renee, Hazuda, Daria J., Simon, Adam J., Miller, Michael D.
Human immunodeficiency virus (HIV) entry into a host cell requires the fusion of virus and cellular membranes that is driven by interaction of the viral envelope glycoproteins gp120 and gp41...
Hazuda, Daria J., Anthony, Neville J., Gomez, Robert P., Jolly, Samson M., Wai, John S., Zhuang, Linghang, ...
The increasing incidence of resistance to current HIV-1 therapy underscores the need to develop antiretroviral agents with new mechanisms of action. Integrase, one of three viral enzymes essential...
Olsen, David B., Eldrup, Anne B., Bartholomew, Linda, Bhat, Balkrishen, Bosserman, Michele R., Ceccacci, Alessandra, ...
Improved treatments for chronic hepatitis C virus (HCV) infection are needed due to the suboptimal response rates and deleterious side effects associated with current treatment options. The...
Ludmerer, Steven W., Graham, Donald J., Boots, Evelyn, Murray, Edward M., Simcoe, Amy, Markel, Eric J., ...
The innate genetic variability characteristic of chronic hepatitis C virus (HCV) infection makes drug resistance a concern in the clinical development of HCV inhibitors. To address this, a transient...
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope
Miller, Michael D., Geleziunas, Romas, Bianchi, Elisabetta, Lennard, Simon, Hrin, Renee, Zhang, Hangchun, ...
HIV-1 entry into cells is mediated by the envelope glycoprotein receptor-binding (gp120) and membrane fusion-promoting (gp41) subunits. The gp41 heptad repeat 1 (HR1) domain is the molecular target...
Jiang, Guochun, Espeseth, Amy, Hazuda, Daria J., Margolis, David M.
Histone deacetylase (HDAC) inhibitors such as valproic acid (VPA) induce the expression of quiescent proviral human immunodeficiency virus type 1 (HIV-1) and may deplete proviral infection in vivo....
Host Cell Factors in HIV Replication: Meta-Analysis of Genome-Wide Studies
Bushman, Frederic D., Malani, Nirav, Fernandes, Jason, D'Orso, Iván, Cagney, Gerard, Diamond, Tracy L., ...
We have analyzed host cell genes linked to HIV replication that were identified in nine genome-wide studies, including three independent siRNA screens. Overlaps among the siRNA screens were very...
Keedy, Kara S., Archin, Nancie M., Gates, Adam T., Espeseth, Amy, Hazuda, Daria J., Margolis, David M.
Silencing of the integrated human immunodeficiency virus type 1 (HIV-1) genome in resting CD4+ T cells is a significant contributor to the persistence of infection, allowing the virus to evade both...